PriceTargets.com logo

NYSE:VOR - Vor Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $46.83
  • Forecasted Upside: 290.28 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$12.00 As of 11/26/2021 05:00 PM ET
▼ -0.48 (-3.85%)

This chart shows the closing price for VOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vor Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VOR

Analyst Price Target is $46.83
▲ +290.28% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $46.83, with a high forecast of $60.00 and a low forecast of $19.00. The average price target represents a 290.28% upside from the last price of $12.00.

This chart shows the closing price for VOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Vor Biopharma. This rating has held steady since March 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/2/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/19/2021JMP SecuritiesInitiated CoverageOutperform$40.00High
5/7/2021B. RileyReiterated RatingBuy$60.00High
3/24/2021B. RileyInitiated CoverageBuy$60.00Low
3/3/2021BarclaysInitiated CoverageOverweight$56.00High
3/2/2021Evercore ISIInitiated CoverageOutperform$48.00High
3/2/2021Stifel NicolausInitiated CoverageBuy$58.00High
3/2/2021The Goldman Sachs GroupInitiated CoverageSell$19.00High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2021
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2021

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vor Biopharma logo
Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $12.00
Low: $11.84
High: $12.96

50 Day Range

MA: $15.27
Low: $12.00
High: $18.02

52 Week Range

Now: $12.00
Low: $11.59
High: $63.62

Volume

59,379 shs

Average Volume

166,412 shs

Market Capitalization

$447.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vor Biopharma?

The following Wall Street research analysts have issued research reports on Vor Biopharma in the last year: B. Riley, Barclays PLC, Evercore ISI, JMP Securities, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for VOR.

What is the current price target for Vor Biopharma?

6 Wall Street analysts have set twelve-month price targets for Vor Biopharma in the last year. Their average twelve-month price target is $46.83, suggesting a possible upside of 290.3%. B. Riley has the highest price target set, predicting VOR will reach $60.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $19.00 for Vor Biopharma in the next year.
View the latest price targets for VOR.

What is the current consensus analyst rating for Vor Biopharma?

Vor Biopharma currently has 1 sell rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VOR will outperform the market and that investors should add to their positions of Vor Biopharma.
View the latest ratings for VOR.

What other companies compete with Vor Biopharma?

Other companies that are similar to Vor Biopharma include C4 Therapeutics, Myovant Sciences, Travere Therapeutics, IVERIC bio, Roivant Sciences, Cronos Group, Community Health Systems, Kadmon, LianBio, Cue Health, Nobilis Health, BioLife Solutions, Aurora Cannabis, Sema4 and Indivior.